This End User License Agreement (“Agreement”) governs your access to, and use of, the mobile applications, software, cloud-based platforms, and related digital services provided by Neurolief Ltd. (“Neurolief”, the “Company”, “we,” “us”, or “our”), in connection with our neuromodulation products, including: (i) Relivion®, an electronic prescription device intended for the treatment of migraine, specifically the Relivion® transcutaneous electrical nerve stimulator is indicated for the acute treatment of migraine with or without aura in patients 18 years of age or older. It is a prescription device to be self-used at home. and (ii) Proliv™Rx external Combined Occipital and Trigeminal Afferent Stimulation (eCOT-AS) (Proliv™Rx System), an electronic device intended for the treatment of depression, specifically the Proliv™Rx System provides focal external Combined Occipital and Trigeminal Afferent Stimulation (eCOT-AS) treatment. It is intended as an adjunctive treatment for Major Depressive Disorder (MDD) in adults who failed to achieve satisfactory improvement from at least one previous antidepressant medication, for use at home or in clinic. It is a prescription-only device (each, together with its associated application and digital environment, a “Product”).
This Agreement applies to your use of (collectively, the “Services”):
- one or more mobile applications provided by Neurolief in connection with the Products (each, an “App”);
- Neurolief’s cloud-based platform, including any web interface, dashboards, and data management tools made available in connection with the Products (the “Platform”); and
- all related digital features, functionalities, questionnaires, web pages and websites (including Neurolief’s website), assessments, treatment flows, data collection and analysis tools, content, support services, and updates provided through the App or the Platform